Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — September 2016

Planlagt Fastgjort Låst Flyttet Genmab
2.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • J Offline
    J Offline
    JKY_VH
    wrote on sidst redigeret af
    #1490

    Se den overskrift kan jeg lide:-) Mange tak hda.

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #1491

      Ritzau er noget mere modereret: https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=407843013&sourcecode=ddk

      1 Reply Last reply
      0
      • N Offline
        N Offline
        NextLifeDK
        wrote on sidst redigeret af
        #1492

        @gentogen: Sådan som jeg læser de forskellige kilder, så har Janssen selv suspenderet studiet, hvorefter (længe efter) FDA har sagt, at det skulle de også. Det er åbenbart først en rigtig nyhed, når FDA har talt.

        1 Reply Last reply
        0
        • G Offline
          G Offline
          GeorgeBest
          wrote on sidst redigeret af
          #1493

          Link Preview Image
          Alvorlige bivirkninger bider ikke på investorernes lyst til Genmab

          Ved middagstid er Genmab dagens bedst præsterende aktie i C20 Cap-indekset.

          favicon

          Finans (finans.dk)

          1 Reply Last reply
          0
          • SolsenS Offline
            SolsenS Offline
            Solsen
            wrote on sidst redigeret af
            #1494

            Hold da kæft et prishop http://finance.yahoo.com/q?s=TBRA%2C+&ql=0

            1 Reply Last reply
            0
            • O Offline
              O Offline
              OHW
              wrote on sidst redigeret af
              #1495

              Ja 600 %, det er da noget der vil noget!

              1 Reply Last reply
              0
              • O Offline
                O Offline
                OHW
                wrote on sidst redigeret af
                #1496

                Desværre ser det ud til at være svært for Gen at fastholde dages gode udvikling. Danske, som har købt mange under det seneste dyk, sælger nu ud.

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote on sidst redigeret af
                  #1497

                  Vi er da stadig i pænt plus....

                  1 Reply Last reply
                  0
                  • R Offline
                    R Offline
                    Repsac
                    wrote on sidst redigeret af
                    #1498

                    ja vi er nøjsomme. 1% om dagen fra nu og til godkendelse. Og så et ordentligt hop. Det er ikke meget vi kræver.

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #1499
                      1. Oktober JNJ Q3 http://finance.yahoo.com/news/johnson-johnson-host-investor-conference-131900080.html
                      1 Reply Last reply
                      0
                      • O Offline
                        O Offline
                        OHW
                        wrote on sidst redigeret af
                        #1500

                        Kommer der salgstal i morgen?

                        1 Reply Last reply
                        0
                        • SolsenS Offline
                          SolsenS Offline
                          Solsen
                          wrote on sidst redigeret af
                          #1501

                          Det mener jeg at have forstået.

                          1 Reply Last reply
                          0
                          • J Offline
                            J Offline
                            JohnW
                            wrote on sidst redigeret af
                            #1502

                            Tænk hvis det var Genmab der steg 600%....:-)

                            1 Reply Last reply
                            0
                            • J Offline
                              J Offline
                              JKY_VH
                              wrote on sidst redigeret af
                              #1503

                              Ja hvis vi fik et bud på 6 gange lukkekursen i går, blev jeg nok lidt blød i knæene:-)

                              1 Reply Last reply
                              0
                              • J Offline
                                J Offline
                                jkj
                                wrote on sidst redigeret af
                                #1504

                                Gilead Sciences, Inc. (NASDAQ:GILD) suggested recently it might be interested in picking up a PARP inhibitor near term, if it can find the right candidate. TESARO Inc (NASDAQ:TSRO)’s late stage asset looks to fit the criteria for a potential asset acquisition, and both the potential, and the realization of this potential, could attract buy volume in the coming months.

                                The data is set for presentation at the Presidential Symposium session at the European Society for Medical Oncology 8 okt

                                1 Reply Last reply
                                0
                                • J Offline
                                  J Offline
                                  jkj
                                  wrote on sidst redigeret af
                                  #1505

                                  Link Preview Image
                                  Looking Ahead To The Potentially Game Changing TESARO Inc (TSRO) Data

                                  TESARO Inc (NASDAQ:TSRO) just announced that the FDA has granted Fast Track designation to its lead ovarian, fallopian tube, or primary peritoneal cancer candidate, and that on the back of the designation...

                                  favicon

                                  Insider Monkey (www.insidermonkey.com)

                                  1 Reply Last reply
                                  0
                                  • J Offline
                                    J Offline
                                    jkj
                                    wrote on sidst redigeret af
                                    #1506

                                    spændende luk venter A/B tager fra

                                    1 Reply Last reply
                                    0
                                    • BulderB Offline
                                      BulderB Offline
                                      Bulder
                                      wrote on sidst redigeret af
                                      #1507

                                      Det blev så Nordea i stedet. Men fin dag markedet taget i betragtning

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #1508

                                        Hvad var det nu det hed, når kursen stiger voldsomt hen imod luk? Vi så det i fredags og nu igen i dag over to omgange.

                                        1 Reply Last reply
                                        0
                                        • I Offline
                                          I Offline
                                          ienk1
                                          wrote on sidst redigeret af
                                          #1509

                                          Scrolling through Genmab’s 15 September presentation at the BofA ML conference last week, we noticed that the pipeline slides now include an FDA breakthrough therapy designation for the Genmab-developed antibody Teprotumumab. This is the fourth BTD for a Genmab-developed drug (Dara has two, Arzerra has one already). This has gone somewhat under the radar

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger